IGC Pharma announced that its Phase 2 CALMA trial evaluating the cannabinoid‑based IGC‑AD1 for agitation in Alzheimer’s disease has achieved roughly 80% patient enrollment. The milestone brings the study closer to enrollment completion, expected in mid‑2026, and positions the company to advance toward database lock and topline data readout.
The company previously reported 70% enrollment in early February 2026, demonstrating steady progress. The 80% figure indicates the trial is in its final recruitment phase, and a new site has been added to expand geographic reach and enhance patient access.
"Reaching 80% enrollment marks an important milestone as we advance toward completion of the CALMA trial. We have entered the final phase of recruitment with strong momentum. Every patient enrolled brings us one step closer to evaluating the full potential of IGC‑AD1. Our focus is now on 100% enrollment and preparing for the data readout that could potentially redefine the treatment landscape for Alzheimer’s disease," said CEO Ram Mukunda.
IGC Pharma has approximately $900,000 in cash as of April 14 2026, following $526,000 in financing in March and $234,000 from a direct offering in January. The company operates in a multi‑billion‑dollar CNS market, with agitation treatments still underserved, positioning IGC‑AD1 to capture a significant share if successful.
The enrollment milestone is a key operational de‑risking event that brings the company closer to a critical data readout that could accelerate the drug’s path to market and enhance its ability to secure future funding or partnerships. The company’s AI‑driven platform and recent intellectual‑property protections further strengthen its competitive position.
Historically, enrollment updates for IGC Pharma have been viewed positively by investors, reflecting confidence in the trial’s progress and the potential for future data.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.